Newsbenzinga
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
· Published
Article summary
Curis shares positive updated clinical data for emavusertib and increases its year-end guidance for the TakeAim CLL study.
An excerpt from the original article.
Comments —
Loading comments…